UBS Group Issues Pessimistic Forecast for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its price objective reduced by investment analysts at UBS Group from $19.00 to $18.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group’s target price suggests a potential upside of 7.63% from the company’s current price.

Several other research firms also recently weighed in on KVUE. Canaccord Genuity Group increased their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Argus raised shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Finally, Citigroup lifted their price target on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Three investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $19.50.

Kenvue Stock Down 3.3%

Shares of KVUE stock traded down $0.58 during trading hours on Tuesday, reaching $16.72. 15,529,809 shares of the stock were exchanged, compared to its average volume of 39,994,559. The business’s fifty day moving average is $17.98 and its two-hundred day moving average is $17.07. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. Kenvue has a 12-month low of $14.02 and a 12-month high of $25.17. The firm has a market capitalization of $32.06 billion, a P/E ratio of 21.66, a P/E/G ratio of 3.89 and a beta of 0.61.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The firm had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. During the same period in the prior year, the firm earned $0.26 earnings per share. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, research analysts expect that Kenvue will post 1.14 EPS for the current fiscal year.

Institutional Trading of Kenvue

A number of institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC grew its holdings in shares of Kenvue by 31.8% during the 4th quarter. Hsbc Holdings PLC now owns 5,106,368 shares of the company’s stock worth $88,231,000 after purchasing an additional 1,230,957 shares during the period. Stance Capital LLC grew its holdings in shares of Kenvue by 14.1% during the 4th quarter. Stance Capital LLC now owns 80,721 shares of the company’s stock worth $1,392,000 after purchasing an additional 9,961 shares during the period. World Investment Advisors grew its holdings in shares of Kenvue by 60.9% during the 4th quarter. World Investment Advisors now owns 19,670 shares of the company’s stock worth $339,000 after purchasing an additional 7,444 shares during the period. Advisortrust Partners LLC purchased a new stake in shares of Kenvue during the 4th quarter worth about $325,000. Finally, Reflection Asset Management purchased a new stake in shares of Kenvue during the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.